Journal
PHARMACOLOGICAL RESEARCH
Volume 182, Issue -, Pages -Publisher
ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.phrs.2022.106334
Keywords
COVID-19; Stemcells; Organdamage; Cytokinestorm; MicroRNA
Categories
Ask authors/readers for more resources
This article discusses the existing data on the use of stem cells for the treatment of COVID-19, highlighting the promising role of stem cells in managing organ damage caused by COVID-19 through inhibition of inflammatory response and promotion of tissue regeneration.
Coronavirus disease 2019 (COVID-19) infection evokes severe proinflammatory storm and pulmonary infection with the number of confirmed cases (more than 200 million) and mortality (5 million) continue to surge globally. A number of vaccines (e.g., Moderna, Pfizer, Johnson/Janssen and AstraZeneca vaccines) have been developed over the past two years to restrain the rapid spread of COVID-19. However, without much of effective drug therapies, COVID-19 continues to cause multiple irreversible organ injuries and is drawing intensive attention for cell therapy in the management of organ damage in this devastating COVID-19 pandemic. For example, mesenchymal stem cells (MSCs) have exhibited promising results in COVID-19 patients. Preclinical and clinical findings have favored the utility of stem cells in the management of COVID-19-induced adverse outcomes via inhibition of cytokine storm and hyperinflammatory syndrome with coinstantaneous tissue regeneration ca-pacity. In this review, we will discuss the existing data with regards to application of stem cells for COVID-19.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available